AI-Designed Drugs by a DeepMind Spinoff Are Headed to Human Trials (www.wired.com)

Isomorphic Labs, a spinoff from Google DeepMind, has announced it will soon begin human trials for drugs designed using its advanced AI technology, specifically leveraging the groundbreaking AlphaFold platform. This significant development marks a pivotal moment in AI-driven drug discovery, as it translates rigorous AI predictions into potential real-world medical applications. Isomorphic Labs, which was founded in 2021, previously aimed to roll out these human trials by the end of 2025 but has now accelerated its timeline. The use of AlphaFold not only revolutionized protein structure prediction but also paved the way for sophisticated drug design, particularly through Isomorphic's new IsoDDE engine, which reportedly doubles AlphaFold 3's accuracy. This advancement allows for the detailed understanding of molecular interactions, essential for effective drug development. With partnerships established with pharmaceutical giants like Eli Lilly and Novartis, Isomorphic Labs is propelling forward in developing targeted therapies with lower doses and reduced side effects. Their ambitious mission to "solve all disease" reflects their commitment to leveraging AI to address complex health challenges, making this an exciting time for AI and ML in biomedicine.